leadf
logo-loader
viewIntercept Pharmaceuticals

Wedbush tips Intercept Pharma shares to more than double in 2017

The broker reckons Intercept can climb to the dizzy heights of US$224 in 2017

liver
Primary biliary cholangitis is an autoimmune disease of the liver that mainly affects women

Wedbush is tipping Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to more than double its share price in the next 12 months in what looks set to be a busy 2017 for the biopharmaceutical firm.

The broker reckons Intercept shares can climb to the dizzy heights of US$224 within the next year or so, well above the US$105 level where they currently sit.

The bullish outlook from Wedbush comes after Intercept received marketing approval from the European Commission for its primary biliary cholangitis (PBC) treatment Ocaliva today.

Similar to the Food and Drug Administration’s (FDA’s) accelerated approval for the treatment in the US, full authorisation from the EC will be based on the successful completion of the ongoing phase IV confirmatory study.

Although it was expected, today’s news is another big milestone in the company’s future, said Wedbush, given the drug’s worldwide earning potential.

“We project ex-US sales of Ocaliva to contribute modestly to revenue in 2017 as ICPT establishes reimbursement agreements on a country-by-country basis,” the broker said in a note today.

“We estimate worldwide gross peak sales for Ocaliva in PBC could reach about US$1.4BN in 2022.”

As with most European launches, it is expected that Germany and France will be the first markets for Ocaliva.

Shares in Intercept were down 3% to US$106.

Quick facts: Intercept Pharmaceuticals

Price: 28.94 USD

NASDAQ:ICPT
Market: NASDAQ
Market Cap: $954.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Namaste releases third quarter financial numbers showing year over year...

Namaste Technologies (CVE: N-OTCMKTS: NXTTF) CEO Meni Morim joined Steve Darling from Proactive to share with viewers the company results from Q-3 2020- Morim noting an improvement in Revenue year over year and a better bottom line. Morim also told Proactive about the real bright spot for the...

3 minutes ago

2 min read